Media stories about Merit Medical Systems (NASDAQ:MMSI) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Merit Medical Systems earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned news stories about the medical instruments supplier an impact score of 46.8138670644892 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of Merit Medical Systems (NASDAQ:MMSI) opened at $40.85 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.78 and a quick ratio of 1.43. Merit Medical Systems has a 52-week low of $22.80 and a 52-week high of $45.50. The stock has a market capitalization of $1,867.40, a price-to-earnings ratio of 29.29, a price-to-earnings-growth ratio of 2.52 and a beta of 1.20.

Merit Medical Systems (NASDAQ:MMSI) last released its earnings results on Wednesday, October 25th. The medical instruments supplier reported $0.32 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.30 by $0.02. Merit Medical Systems had a negative return on equity of 2.15% and a negative net margin of 1.99%. The business had revenue of $179.30 million during the quarter, compared to the consensus estimate of $181.28 million. During the same period last year, the business posted $0.26 earnings per share. The business’s revenue for the quarter was up 14.2% on a year-over-year basis. equities analysts predict that Merit Medical Systems will post 1.27 EPS for the current fiscal year.

MMSI has been the topic of a number of recent analyst reports. Canaccord Genuity lifted their price target on Merit Medical Systems from $45.00 to $47.50 and gave the stock a “buy” rating in a report on Thursday, October 26th. Craig Hallum reiterated a “buy” rating and set a $50.00 price target (up from $42.00) on shares of Merit Medical Systems in a report on Thursday, July 27th. Zacks Investment Research lowered Merit Medical Systems from a “buy” rating to a “hold” rating in a report on Tuesday, October 3rd. Piper Jaffray Companies reiterated a “buy” rating and set a $45.00 price target on shares of Merit Medical Systems in a report on Friday, July 28th. Finally, UBS AG lowered Merit Medical Systems from a “strong-buy” rating to an “outperform” rating in a report on Monday, August 28th. One analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $41.65.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2017/11/16/merit-medical-systems-mmsi-given-daily-news-sentiment-rating-of-0-19.html.

In other news, Director Kent W. Stanger sold 1,930 shares of Merit Medical Systems stock in a transaction on Monday, September 11th. The stock was sold at an average price of $42.02, for a total value of $81,098.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.00% of the stock is currently owned by insiders.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a manufacturer and marketer of disposable medical devices used in a range of interventional, diagnostic and therapeutic medical procedures. The Company operates in two segments: cardiovascular and endoscopy. The cardiovascular segment consists of cardiology and radiology devices, which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases, and includes embolotherapeutic, cardiac rhythm management (CRM), electrophysiology (EP), and interventional oncology and spine devices.

Insider Buying and Selling by Quarter for Merit Medical Systems (NASDAQ:MMSI)

Receive News & Ratings for Merit Medical Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.